CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Strength||150 mg/vial and 440 mg/vial|
|Tumour Type||Breast / Gastrointestinal|
|Indication||Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar|
|Funding Request||For the treatment of patients with early stage breast cancer with ECOG 0-1 status, whose tumours overexpress HER2, following surgery and after chemotherapy, following adjuvant chemotherapy consisting of doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel, in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin / the treatment of patients with MBC whose tumours overexpress HER2 / in combination with capecitabine or intravenous 5-fluorouracil and cisplatin is indicated for the treatment of patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease|
|Clarification||Mylan Canada has requested a voluntary withdrawal of the pCODR 10169 submission for Ogivri.|
|Pre Noc Submission||Yes|
|NOC Date||May 7, 2019|
|Manufacturer||BGP Pharma ULC|
|Sponsor||BGP Pharma ULC|
|Submission Date||December 18, 2018|
|Submission Deemed Complete||January 9, 2019|
|Stakeholder Input Deadline ‡||January 9, 2019|
|Check-point meeting (target date)|
|pERC Meeting (target date)|
|Initial Recommendation Issued (target date)|
|Feedback Deadline (target date) ‡|
|pERC Reconsideration Meeting (target date)|
|Final Recommendation Issued (target date)|
|Notification to Implement Issued|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.